相关实验视频

Updated: Jun 21, 2025

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

根据人类转运器-1遗传多态化基因的Cefaclor药物动力学多样性的基于结构的分析

Ji-Hun Jang¹, Seung-Hyun Jeong^1,2

¹College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si 57922, Republic of Korea.

International journal of molecular sciences

|July 13, 2024

概括

溶解载体家族-15-成员-1 (SLC15A1) 异构5和16中的遗传变异不会显著影响氏体的药理动力学或与人体载体-1 (PEPT1) 的相互作用. 这些多态性不太可能是塞法克洛尔药物动力学多样性的主要原因.

科学领域:

药理学药理学是指药理学的学科.
遗传学遗传学是一个
生物化学生物化学

背景情况:

塞法克由人体载体-1 (PEPT1) 运输,其编码由溶解物载体家族-15-成员-1 (SLC15A1) 编码.
已经讨论了Cefaclor的个人间的药理动力学变异性,重点是SLC15A1遗传多态.

研究的目的:

分析在SLC15A1第5和第16个外形中与遗传多态相对应的塞法克的药物动力学变化.
通过分子建模,评估这些SLC15A1多态体对PEPT1的基于结构的功能影响.

主要方法:

整合之前的塞法克洛生物等价性数据与SLC15A1外基因组5和16的基因定型.
种群药动力学建模以评估SLC15A1多态的影响.
PEPT1分子建模,分析SLC15A1基因变异对Cefaclor相互作用的结构和功能影响.

主要成果:

不同的SLC15A1基因组之间没有观察到塞法克的药理动力学显著差异.
在5号和16号外因子中的SLC15A1多态性并未被确定为人口药理动力学模型中的显著共变量.
分子建模表明,在第5和第16个外体中的SLC15A1多态性并不会显著改变cefaclor结合或PEPT1的结构稳定性.

结论:

在SLC15A1第5和第16个异构体中的遗传多态性似乎并不是塞法克的药物动力学变异性的主要决定因素.
这些特定的SLC15A1多态体对PEPT1的结构和功能影响有限,这表明其他因素有助于塞法克的药物动力学多样性.

关键词:

这就是PEPT1的原因.在SLC15A1第5和第16个异构体中,SLC15A1 这就是CefaChlor.个体间的变异性.药物动力学药物动力学

更多相关视频

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

相关概念视频

Hepatic Drug Clearance: Role of Transporters

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Nonlinear Pharmacokinetics: Role of Transporters

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...

Carrier-Mediated Transport

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...